Travere Therapeutics Inc Ordinary Shares TVTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
-
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
-
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
-
Travere Therapeutics Announces Planned Chief Executive Officer Transition
-
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Travere Therapeutics to Participate at Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $56.85
- Day Range
- $56.34–57.53
- 52-Week Range
- $22.59–68.73
- Bid/Ask
- $56.90 / $56.92
- Shares Outstanding
- 94.26M
- Market Cap
- $5.37B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 163.50
- Price/Sales
- 8.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 497
- Website
- https://www.travere.com
Valuation
|
Metric
|
TVTX
|
|---|---|
Price/Earnings (Normalized) | 163.50 |
Price/Book Value | 218.33 |
Price/Sales | 8.77 |
Price/Cash Flow | 55.18 |
Price/Earnings
TVTX
Financial Strength
|
Metric
|
TVTX
|
|---|---|
Quick Ratio | 3.75 |
Current Ratio | 4.05 |
Interest Coverage | −7.30 |
Quick Ratio
TVTX
Profitability
|
Metric
|
TVTX
|
|---|---|
Return on Assets (Normalized) | 13.29% |
Return on Equity (Normalized) | 117.85% |
Return on Invested Capital (Normalized) | 16.94% |
Return on Assets
TVTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|FcJnN> | LOCK|d$xH | $128B | |||
| Moderna Inc
MRNA
| LOCK|ps&Xx>m | LOCK|%H | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<>BvGRM | LOCK|Z^@n | $76B | |||
| argenx SE ADR
ARGX
| LOCK|RNp%$> | LOCK|RX? | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|zk&<#M | LOCK|G% | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^%jzt!# | LOCK|q&!y | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|J%#R&@< | LOCK|H&!cB | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|gT?gX< | LOCK|## | $24B | |||
| Incyte Corp
INCY
| LOCK|y&<G&zn | LOCK|CV^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>XzVsb | LOCK|<@ | $15B |
United States